



Biological treatment during COVID-19 outbreak

Won Sriwijitalai & Viroj Wiwanitkit

To cite this article: Won Sriwijitalai & Viroj Wiwanitkit (2020): Biological treatment during COVID-19 outbreak, Journal of Dermatological Treatment, DOI: [10.1080/09546634.2020.1749548](https://doi.org/10.1080/09546634.2020.1749548)

To link to this article: <https://doi.org/10.1080/09546634.2020.1749548>



Accepted author version posted online: 28 Mar 2020.
Published online: 13 Apr 2020.



Submit your article to this journal [↗](#)



Article views: 800



View related articles [↗](#)



View Crossmark data [↗](#)



Biological treatment during COVID-19 outbreak

Dear Editor,

We read the publication on 'Should patients stop their biologic treatment during the COVID-19 pandemic' and found that it is very interesting (1). Bashyam and Feldman raised an interesting issue for discussion regarding using biological treatment during COVID-19 outbreak (1). In fact, although there are infected patients worldwide, there has never any reports on biological treatment associated COVID-19. Whether, there is any problem relating to corticosteroid and TNF- α inhibitors in coronavirus infection is an interesting question. In a previous animal model study on coronavirus infection, TNF- α inhibitors did not deteriorate the disease course (2). Atanasova et al. found that blocking of TNF- α alone was not sufficient to ameliorate the disease (2). The immunopathology of the new disease is still largely unknown. It might be too early to conclude whether biological treatment should be ceased during COVID-19 outbreak.

Disclosure statement

No potential conflict of interest was reported by the author(s).

References

1. Bashyam AM, Feldman SR. Should patients stop their biologic treatment during the COVID-19 pandemic. *J Dermatolog Treat.* 2020;Mar 19:1–2. [Epub ahead of print]
2. Atanasova K, Van Gucht S, Van Reeth K. Anti-TNF-alpha therapy does not ameliorate disease in a model of acute virus-endotoxin mediated respiratory disease in pigs. *Vet Immunol Immunopathol.* 2010;137(1-2):12–19.

Won Sriwijitalai
RVT Medical Center, Bangkok, Thailand
 wonsriwi@gmail.com

Viroj Wiwanitkit
Dr DY Patil University, Pune, India
Hainan Medical University, Haikou, China

© 2020 Taylor & Francis Group, LLC